Patents by Inventor Yonggang Wei

Yonggang Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12221449
    Abstract: Provided is a new compound capable of effectively inhibiting ATX. The compound is represented by formula I, or the compound is a tautomer, a stereoisomer, a hydrate, a solvate, a salt, or a prodrug of the compound represented by formula I. In formula (I), R1 and R2 are independently selected from —H or —CH3, provided that: R1 and R2 are not —H at the same time or are not —CH3 at the same time.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: February 11, 2025
    Assignee: WUHAN HUMANWELL INNOVATIVE DRUG RESEARCH AND DEVELOPMENT CENTER LIMITED COMPANY
    Inventors: Xuejun Zhang, Dabing Ye, Lie Li, Jie Shen, Xiaohua Ding, Hongna Sun, Zhe Liu, Yang Zang, Yonggang Wei
  • Publication number: 20240391921
    Abstract: The present invention relates to a crystal form of an imidazolinone derivative. The present invention further relates to a crystal form of a substituted imidazolinone derivative and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof in the preparation of a DNA-PK inhibitor. Specifically, the present invention relates to crystal forms I-VI of the compound as represented by formula (A) and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof in the preparation of a DNA-PK inhibitor.
    Type: Application
    Filed: September 23, 2022
    Publication date: November 28, 2024
    Inventors: Xuezhen XU, Feiquan LEI, Lvxue HE, Yonggang WEI, Yi SUN
  • Publication number: 20240158406
    Abstract: The present application relates to a piperazine-based compound and a composition thereof, and the use thereof in the manufacture of an anti-tumor medicament.
    Type: Application
    Filed: November 21, 2023
    Publication date: May 16, 2024
    Inventors: Yonggang WEI, Yuqin ZHU, Hongzhu CHU, Fei YE, Wutong DENG, Wei LIU, Yi SUN
  • Patent number: 11976054
    Abstract: The present invention relates to an amide derivative and use thereof in medicine, and specifically to an amide derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, deuteride, prodrug, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition containing the same, and use of the compound or the composition disclosed herein in preparing an NLRP3 inhibitor.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: May 7, 2024
    Assignee: Chengdu Baiyu Pharmaceutical Co., Ltd.
    Inventors: Yonggang Wei, Hongzhu Chu, Yue Gao, Lingfeng Xiong, Guizhuan Su, Meiwei Wang, Yi Sun
  • Publication number: 20240024465
    Abstract: An application of collagen peptide in the preparation of an allergen preparation auxiliary material. For an allergen preparation, the auxiliary material thereof does not contain biological macromolecules, but contains the collagen peptide, avoiding the risk of potential allergies caused by the introduction of an inactive substance protein. The allergen preparation containing no biological macromolecule auxiliary materials can be stored stably for three years at room temperature. For allergic patients, the allergen preparation is a highly effective, stable and safe drug.
    Type: Application
    Filed: May 28, 2021
    Publication date: January 25, 2024
    Applicant: GLALLERGEN CO., LTD.
    Inventors: Caiming BAI, Yan ZHOU, Liping JIAN, Tingting GUO, Min JIANG, Lixia JIA, Yonggang WEI
  • Publication number: 20240018079
    Abstract: Disclosed is a method for purifying cannabinoid compounds that enables cannabinoid compounds to be obtained more economically and with a better purification effect.
    Type: Application
    Filed: November 25, 2021
    Publication date: January 18, 2024
    Inventors: Yi SUN, Xuezhen XU, Jing ZHANG, Yonggang WEI
  • Publication number: 20230227482
    Abstract: Tetrahydrocannabinol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description
    Type: Application
    Filed: January 7, 2021
    Publication date: July 20, 2023
    Inventors: Jing ZHANG, Xuezhen XU, Yonggang WEI, Hongzhu CHU, Fuqiang ZHAO, Guizhuan SU, Meiwei WANG, Yi SUN
  • Publication number: 20230165867
    Abstract: The present application relates to imidazolidinone derivatives and medical use thereof, and in particular relates to pyrimidine derivatives represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or co-crystals thereof, a pharmaceutical composition comprising the same, and use of the compound or pharmaceutical composition according to the present application in the manufacture of a medicament for treatment of cancer.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 1, 2023
    Inventors: Yonggang WEI, Xuezhen XU, Hongzhu CHU, Lvxue HE, Feiquan LEI, Jie YAN, Yang HE, Meiwei WANG, Guizhuan SU, Bing LIU, Yi SUN
  • Publication number: 20230059087
    Abstract: Cannabidiol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description
    Type: Application
    Filed: January 7, 2021
    Publication date: February 23, 2023
    Inventors: Xibing ZHOU, Jing ZHANG, Xuezhen XU, Yonggang WEI, Hongzhu CHU, Fuqiang ZHAO, Guizhuan SU, Meiwei WANG, Yi SUN
  • Publication number: 20230002425
    Abstract: Cannabidiol derivatives and medical use thereof, in particular to compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of the substituents in general formula (I) are the same as those in the description.
    Type: Application
    Filed: January 7, 2021
    Publication date: January 5, 2023
    Inventors: Xuezhen XU, Jing ZHANG, Yonggang WEI, Hongzhu CHU, Fuqiang ZHAO, Guizhuan SU, Meiwei WANG, Yi SUN
  • Publication number: 20220411392
    Abstract: The present invention relates to an amide derivative and use thereof in medicine, and specifically to an amide derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, deuteride, prodrug, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition containing the same, and use of the compound or the composition disclosed herein in preparing an NLRP3 inhibitor.
    Type: Application
    Filed: November 12, 2020
    Publication date: December 29, 2022
    Applicant: Chengdu Baiyu Pharmaceutical Co., Ltd.
    Inventors: Yonggang Wei, Hongzhu Chu, Yue Gao, Lingfeng Xiong, Guizhuan Su, Meiwei Wang, Yi Sun
  • Publication number: 20220402920
    Abstract: The present invention relates to a purine derivative and use thereof in medicine, and in particular to a pyrimidine derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, prodrug, deuteride, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition comprising the same, and use of the compound or composition of the present invention in the field of preparation of a DNA-PK inhibitor, wherein the substituents in general formula (I) are defined in the same way as in the specification
    Type: Application
    Filed: December 30, 2020
    Publication date: December 22, 2022
    Inventors: Yonggang Wei, Xuezhen Xu, Hongzhu Chu, Lvxue He, Xiangyu Meng, Meiwei Wang, Guizhuan Su, Bing Liu, Yi Sun
  • Publication number: 20220064172
    Abstract: Provided is a new compound capable of effectively inhibiting ATX. The compound is represented by formula I, or the compound is a tautomer, a stereoisomer, a hydrate, a solvate, a salt, or a prodrug of the compound represented by formula I. In formula (I), R1 and R2 are independently selected from —H or —CH3, provided that: R1 and R2 are not —H at the same time or are not —CH3 at the same time.
    Type: Application
    Filed: January 22, 2020
    Publication date: March 3, 2022
    Inventors: Xuejun ZHANG, Dabing YE, Lie LI, Jie SHEN, Xiaohua DING, Hongna SUN, Zhe LIU, Yang ZANG, Yonggang WEI
  • Patent number: 11209128
    Abstract: The present invention discloses a plug-in lamp holder and a lamp comprising the plug-in lamp holder.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: December 28, 2021
    Assignee: CE LIGHTING LTD.
    Inventor: Yonggang Wei
  • Publication number: 20210205291
    Abstract: Provided are a compound represented by formula (I) or a stereoisomer, hydrate, metabolite, solvate, pharmaceutically acceptable salt, eutectic mixture, or prodrug thereof, and a preparation method thereof, and an application for preparing a pharmaceutical product for treating a disease related to obstructed airways, wherein each substituent in the compound represented by formula (I) is as described in the specification.
    Type: Application
    Filed: January 20, 2017
    Publication date: July 8, 2021
    Applicant: Sichuan Haisco Pharmaceutical Co., Ltd.
    Inventors: Yonggang WEI, Guanpeng QUI, Bolin LEI, Song WANG
  • Publication number: 20210172569
    Abstract: The present invention discloses a plug-in lamp holder and a lamp comprising the plug-in lamp holder.
    Type: Application
    Filed: October 16, 2020
    Publication date: June 10, 2021
    Inventor: Yonggang WEI
  • Patent number: 11014964
    Abstract: The invention provides a peptide amide compound represented by the general general formula (I), a preparation method thereof, and a medical application thereof. The compound has a novel structure, better biological activity, and better analgesic effect.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: May 25, 2021
    Assignee: Sichuan Haisco Pharmaceutical Co., Ltd.
    Inventors: Chen Zhang, Anbang Huang, Fei Ye, Longbin Huang, Zhenggang Huang, Jianmin Wang, Yonggang Wei, Pangke Yan, Wei Zheng
  • Publication number: 20200172573
    Abstract: The invention provides a peptide amide compound represented by the general general formula (I), a preparation method thereof, and a medical application thereof. The compound has a novel structure, better biological activity, and better analgesic effect.
    Type: Application
    Filed: July 19, 2018
    Publication date: June 4, 2020
    Applicant: Sichuan Haisco Pharmaceutical Co., Ltd.
    Inventors: Chen ZHANG, Anbang HUANG, Fei YE, Longbin HUANG, Zhenggang HUANG, Jianmin WANG, Yonggang WEI, Pangke YAN, Wei ZHENG
  • Publication number: 20190185461
    Abstract: A compound represented by general formula (I), or a stereoisomer, a hydrate, a metabolite, a solvate, a pharmaceutically acceptable salt, a cocrystal, or a prodrug thereof, the preparation method thereof, and use thereof in the manufacture of a medicament for treatment of an airway obstructive disease, wherein the substituents are defined as in the specification.
    Type: Application
    Filed: July 12, 2016
    Publication date: June 20, 2019
    Applicant: Sichuan Haisco Pharmaceutical Co., Ltd.
    Inventors: Yonggang WEI, Guanpeng QUI, Bolin LEI, Yonghua LU, Suxin ZHENG
  • Patent number: 10174020
    Abstract: Provided is a pyridone or pyrimidone derivative(s) represented by general formula (I) and its preparation method and use. Substituents of the compound of general formula (I) are defined the same as in the specification.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: January 8, 2019
    Assignee: SICHUAN HAISCO PHARMACEUTICAL CO., LTD.
    Inventors: Yonggang Wei, Guanpeng Qiu, Suxin Zheng, Bolin Lei, Yan Yu, Yashu Chen